6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.5	CD	2.5	2.5	2.5	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Fluid	NNP	fluid	fluid	fluid	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Pfizer	NNP	pfizer	pfizer	pfizer	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
438	CD	438	438	438	N	O
-	:	-	-	-	N	O
1985	CD	1985	1985	1985	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
include	VBP	include	include	includ	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
(	(	(	(	(	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fluid	JJ	fluid	fluid	fluid	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
grade	NN	grade	grade	grade	N	O
reported	VBD	reported	reported	report	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
20%	CD	20%	20%	20%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
safety	NN	safety	safety	safeti	N	O
population	NN	population	population	popul	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
546	CD	546	546	546	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
diarrhea	VBN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
82%	CD	82%	82%	82%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
46%	CD	46%	46%	46%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
thrombocytopenia	EX	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
41%	CD	41%	41%	41%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
39%	CD	39%	39%	39%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
37%	CD	37%	37%	37%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
35%	CD	35%	35%	35%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
26%	CD	26%	26%	26%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Imatinib	NNP	imatinib	imatinib	imatinib	N	O
-	:	-	-	-	N	O
Resistant	NN	resistant	resistant	resist	N	O
or	CC	or	or	or	N	O
-	:	-	-	-	N	O
Intolerant	JJ	intolerant	intolerant	intoler	N	O
Ph	NNP	ph	ph	ph	Y	O
Chronic	NNP	chronic	chronic	chronic	N	O
Phase	NNP	phase	phase	phase	N	O
(	(	(	(	(	N	O
CP	NNP	cp	cp	cp	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Accelerated	NNP	accelerated	accelerated	acceler	N	O
Phase	NNP	phase	phase	phase	N	O
(	(	(	(	(	N	O
AP	NNP	ap	ap	ap	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Blast	NNP	blast	blast	blast	N	O
Phase	NNP	phase	phase	phase	N	O
(	(	(	(	(	N	O
BP	NNP	bp	bp	bp	Y	O
)	)	)	)	)	N	O
CML	NNP	cml	cml	cml	Y	O

The	DT	the	the	the	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
Phase	NNP	phase	phase	phase	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Ph	NNP	ph	ph	ph	Y	O
chronic	NN	chronic	chronic	chronic	N	O
,	,	,	,	,	N	O
accelerated	VBN	accelerated	accelerated	acceler	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
blast	VB	blast	blast	blast	N	O
phase	NN	phase	phase	phase	N	O
chronic	JJ	chronic	chronic	chronic	N	O
myelogenous	JJ	myelogenous	myelogenous	myelogen	N	O
leukemia	NN	leukemia	leukemia	leukemia	Y	O
(	(	(	(	(	N	O
CML	NNP	cml	cml	cml	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
resistance	NN	resistance	resistance	resist	N	O
or	CC	or	or	or	N	O
intolerance	NN	intolerance	intolerance	intoler	N	O
to	TO	to	to	to	N	O
prior	VB	prior	prior	prior	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
population	NN	population	population	popul	N	O
(	(	(	(	(	N	O
received	VBN	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
)	)	)	)	)	N	O
included	VBD	included	included	includ	N	O
546	CD	546	546	546	N	O
CML	NNP	cml	cml	cml	Y	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O

287	CD	287	287	287	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CP	NNP	cp	cp	cp	N	O
CML	NNP	cml	cml	cml	Y	O
previously	RB	previously	previously	previous	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
imatinib	NN	imatinib	imatinib	imatinib	N	O
only	RB	only	only	onli	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
24	CD	24	24	24	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
dose	JJ	dose	dose	dose	N	O
intensity	NN	intensity	intensity	intens	N	O
of	IN	of	of	of	N	O
484	CD	484	484	484	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

119	CD	119	119	119	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CP	NNP	cp	cp	cp	N	O
CML	NNP	cml	cml	cml	Y	O
previously	RB	previously	previously	previous	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
both	DT	both	both	both	N	O
imatinib	NNS	imatinib	imatinib	imatinib	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
additional	JJ	additional	additional	addit	N	O
TKI	NNP	tki	tki	tki	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
9	CD	9	9	9	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
dose	JJ	dose	dose	dose	N	O
intensity	NN	intensity	intensity	intens	N	O
of	IN	of	of	of	N	O
475	CD	475	475	475	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

140	CD	140	140	140	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
advanced	JJ	advanced	advanced	advanc	N	O
phase	NN	phase	phase	phase	N	O
CML	NNP	cml	cml	cml	Y	O
including	VBG	including	including	includ	N	O
76	CD	76	76	76	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
AP	NNP	ap	ap	ap	N	O
CML	NNP	cml	cml	cml	Y	O
and	CC	and	and	and	N	O
64	CD	64	64	64	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
BP	NNP	bp	bp	bp	Y	O
CML	NNP	cml	cml	cml	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
AP	NNP	ap	ap	ap	N	O
CML	NNP	cml	cml	cml	Y	O
and	CC	and	and	and	N	O
BP	NNP	bp	bp	bp	Y	O
CML	NNP	cml	cml	cml	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
10	CD	10	10	10	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
dose	NN	dose	dose	dose	N	O
intensity	NN	intensity	intensity	intens	N	O
was	VBD	was	wa	wa	N	O
483	CD	483	483	483	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
500	CD	500	500	500	N	O
mg	NNS	mg	mg	mg	N	O
day	NN	day	day	day	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
AP	NNP	ap	ap	ap	N	O
CML	NNP	cml	cml	cml	Y	O
and	CC	and	and	and	N	O
BP	NNP	bp	bp	bp	Y	O
CML	NNP	cml	cml	cml	Y	O
cohorts	NNS	cohorts	cohort	cohort	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
identifies	NNS	identifies	identifies	identifi	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
and	CC	and	and	and	N	O
grades	NNS	grades	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
CML	NNP	cml	cml	cml	Y	O
safety	NN	safety	safety	safeti	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
or	CC	or	or	or	N	O
Greater	NNP	greater	greater	greater	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CML	NNP	cml	cml	cml	Y	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Chronic	JJ	chronic	chronic	chronic	N	O
Phase	NNP	phase	phase	phase	N	O
CMLN	NNP	cmln	cmln	cmln	N	O
406	CD	406	406	406	N	O
Advanced	NNP	advanced	advanced	advanc	N	O
Phase	NNP	phase	phase	phase	N	O
CMLN	NNP	cmln	cmln	cmln	N	O
140	CD	140	140	140	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Advanced	NNP	advanced	advanced	advanc	N	O

Phase	NNP	phase	phase	phase	N	O
CML	NNP	cml	cml	cml	Y	O
includes	VBZ	includes	includes	includ	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Accelerated	NNP	accelerated	accelerated	acceler	N	O
Phase	NNP	phase	phase	phase	N	O
and	CC	and	and	and	N	O
Blast	NNP	blast	blast	blast	N	O
Phase	NNP	phase	phase	phase	N	O
CML	NNP	cml	cml	cml	Y	O

Diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction

84	CD	84	84	84	N	O
9	CD	9	9	9	N	O
76	CD	76	76	76	N	O
5	CD	5	5	5	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
46	CD	46	46	46	N	O
1	CD	1	1	1	N	O
47	CD	47	47	47	N	O
2	CD	2	2	2	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
40	CD	40	40	40	N	O
1	CD	1	1	1	N	O
29	CD	29	29	29	N	O
5	CD	5	5	5	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
40	CD	40	40	40	N	O
26	CD	26	26	26	N	O
42	CD	42	42	42	N	O
37	CD	37	37	37	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
37	CD	37	37	37	N	O
3	CD	3	3	3	N	O
42	CD	42	42	42	N	O
4	CD	4	4	4	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
34	CD	34	34	34	N	O
8	CD	8	8	8	N	O
35	CD	35	35	35	N	O
4	CD	4	4	4	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
26	CD	26	26	26	N	O
1	CD	1	1	1	N	O
20	CD	20	20	20	N	O
4	CD	4	4	4	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
23	CD	23	23	23	N	O
9	CD	9	9	9	N	O
37	CD	37	37	37	N	O
26	CD	26	26	26	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
22	CD	22	22	22	N	O
1	CD	1	1	1	N	O
36	CD	36	36	36	N	O
3	CD	3	3	3	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
alanine	JJ	alanine	alanine	alanin	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
20	CD	20	20	20	N	O
7	CD	7	7	7	N	O
10	CD	10	10	10	N	O
5	CD	5	5	5	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
20	CD	20	20	20	N	O
1	CD	1	1	1	N	O
18	CD	18	18	18	N	O
4	CD	4	4	4	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
20	CD	20	20	20	N	O
0	CD	0	0	0	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
aspartate	JJ	aspartate	aspartate	aspart	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
16	CD	16	16	16	N	O
4	CD	4	4	4	N	O
11	CD	11	11	11	N	O
3	CD	3	3	3	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
16	CD	16	16	16	N	O
11	CD	11	11	11	N	O
19	CD	19	19	19	N	O
18	CD	18	18	18	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O
13	CD	13	13	13	N	O
0	CD	0	0	0	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O
7	CD	7	7	7	N	O
1	CD	1	1	1	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O
19	CD	19	19	19	N	O
6	CD	6	6	6	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
Phase	NNP	phase	phase	phase	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
QTcF	NNP	qtcf	qtcf	qtcf	N	B-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
500	CD	500	500	500	N	I-AdverseReaction
milliseconds	NNS	milliseconds	millisecond	millisecond	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
or	CC	or	or	or	N	O
significant	JJ	significant	significant	signific	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
including	VBG	including	including	includ	N	O
QT	NNP	qt	qt	qt	N	O
interval	JJ	interval	interval	interv	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
were	VBD	were	were	were	N	O
excluded	VBN	excluded	excluded	exclud	N	O
by	IN	by	by	by	N	O
protocol	NN	protocol	protocol	protocol	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
identifies	NNS	identifies	identifies	identifi	N	O
the	DT	the	the	the	N	O
clinically	RB	clinically	clinically	clinic	N	O
relevant	JJ	relevant	relevant	relev	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
test	NN	test	test	test	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
CML	NNP	cml	cml	cml	Y	O
safety	NN	safety	safety	safeti	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Number	NNP	number	number	number	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Clinically	NNP	clinically	clinically	clinic	N	O
Relevant	NNP	relevant	relevant	relev	N	O
or	CC	or	or	or	N	O
Severe	NNP	severe	severe	sever	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
Laboratory	JJ	laboratory	laboratory	laboratori	N	O
Test	NNP	test	test	test	N	O
Abnormalities	NNPS	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CML	NNP	cml	cml	cml	Y	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
Safety	NNP	safety	safety	safeti	N	O
Population	NNP	population	population	popul	N	O

Chronic	JJ	chronic	chronic	chronic	N	O
Phase	NNP	phase	phase	phase	N	O
CML	NNP	cml	cml	cml	Y	O
Advanced	NNP	advanced	advanced	advanc	N	O
Phase	NNP	phase	phase	phase	N	O
CML	NNP	cml	cml	cml	Y	O
All	NNP	all	all	all	N	O
CP	NNP	cp	cp	cp	N	O
and	CC	and	and	and	N	O
AdvP	NNP	advp	advp	advp	N	O
CML	NNP	cml	cml	cml	Y	O

N	NNP	n	n	n	N	O
406	CD	406	406	406	N	O
N	NNP	n	n	n	N	O
140	CD	140	140	140	N	O
N	NNP	n	n	n	N	O
546	CD	546	546	546	N	O

n	RB	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
n	FW	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Parameters	NNS	parameters	parameter	paramet	N	O

Platelet	NNP	platelet	platelet	platelet	N	B-AdverseReaction
Count	NNP	count	count	count	N	I-AdverseReaction
(	(	(	(	(	N	O
Low	NNP	low	low	low	N	I-AdverseReaction
)	)	)	)	)	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
50	CD	50	50	50	N	B-Severity
10	CD	10	10	10	N	I-Severity
9	CD	9	9	9	N	I-Severity
L	NNP	l	l	l	N	I-Severity
102	CD	102	102	102	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
)	)	)	)	)	N	O
80	CD	80	80	80	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
182	CD	182	182	182	N	O
(	(	(	(	(	N	O
33	CD	33	33	33	N	O
)	)	)	)	)	N	O

Absolute	NNP	absolute	absolute	absolut	N	B-AdverseReaction
Neutrophil	NNP	neutrophil	neutrophil	neutrophil	N	I-AdverseReaction
Count	NNP	count	count	count	N	I-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
1	CD	1	1	1	N	I-AdverseReaction
10	CD	10	10	10	N	I-AdverseReaction
9	CD	9	9	9	N	I-AdverseReaction
L	NNP	l	l	l	N	I-AdverseReaction
74	CD	74	74	74	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O
52	CD	52	52	52	N	O
(	(	(	(	(	N	O
37	CD	37	37	37	N	O
)	)	)	)	)	N	O
126	CD	126	126	126	N	O
(	(	(	(	(	N	O
23	CD	23	23	23	N	O
)	)	)	)	)	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
(	(	(	(	(	N	O
Low	NNP	low	low	low	N	I-AdverseReaction
)	)	)	)	)	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
80	CD	80	80	80	N	B-Severity
g	JJ	g	g	g	N	I-Severity
L	NNP	l	l	l	N	I-Severity
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
49	CD	49	49	49	N	O
(	(	(	(	(	N	O
35	CD	35	35	35	N	O
)	)	)	)	)	N	O
102	CD	102	102	102	N	O
(	(	(	(	(	N	O
19	CD	19	19	19	N	O
)	)	)	)	)	N	O

Biochemistry	NN	biochemistry	biochemistry	biochemistri	N	O
Parameters	NNS	parameters	parameter	paramet	N	O

SGPT	NNP	sgpt	sgpt	sgpt	Y	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
5.0	CD	5.0	5.0	5.0	N	I-AdverseReaction
ULN	JJ	uln	uln	uln	N	I-AdverseReaction
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
47	CD	47	47	47	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O

SGOT	NNP	sgot	sgot	sgot	Y	B-AdverseReaction
AST	NNP	ast	ast	ast	N	B-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
5.0	CD	5.0	5.0	5.0	N	I-AdverseReaction
ULN	JJ	uln	uln	uln	N	I-AdverseReaction
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Lipase	NNP	lipase	lipase	lipas	Y	B-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
2	CD	2	2	2	N	I-AdverseReaction
ULN	JJ	uln	uln	uln	N	I-AdverseReaction
33	CD	33	33	33	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O

Phosphorus	NNP	phosphorus	phosphorus	phosphoru	Y	B-AdverseReaction
(	(	(	(	(	N	O
Low	NNP	low	low	low	N	I-AdverseReaction
)	)	)	)	)	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
0.6	CD	0.6	0.6	0.6	N	B-Severity
mmol	JJ	mmol	mmol	mmol	N	I-Severity
L	NNP	l	l	l	N	I-Severity
30	CD	30	30	30	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
40	CD	40	40	40	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O

Total	JJ	total	total	total	N	B-AdverseReaction
Bilirubin	NNP	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
3.0	CD	3.0	3.0	3.0	N	I-AdverseReaction
ULN	JJ	uln	uln	uln	N	I-AdverseReaction
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Additional	JJ	additional	additional	addit	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
Multiple	NNP	multiple	multiple	multipl	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O

following	VBG	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

They	PRP	they	they	they	N	O
represent	VBP	represent	represent	repres	N	O
an	DT	an	an	an	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
870	CD	870	870	870	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Ph	NNP	ph	ph	ph	Y	O
leukemia	NN	leukemia	leukemia	leukemia	Y	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
agent	NN	agent	agent	agent	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
by	IN	by	by	by	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
ranked	VBN	ranked	ranked	rank	N	O
by	IN	by	by	by	N	O
frequency	NN	frequency	frequency	frequenc	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
included	VBN	included	included	includ	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
clinical	JJ	clinical	clinical	clinic	N	O
relevance	NN	relevance	relevance	relev	N	O
and	CC	and	and	and	N	O
ranked	VBN	ranked	ranked	rank	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
seriousness	NN	seriousness	seriousness	serious	N	O
within	IN	within	within	within	N	O
each	DT	each	each	each	N	O
category	NN	category	category	categori	N	O
.	.	.	.	.	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
febrile	NN	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
pericardial	JJ	pericardial	pericardial	pericardi	N	B-AdverseReaction
effusion	NN	effusion	effusion	effus	Y	I-AdverseReaction
;	:	;	;	;	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
-	:	-	-	-	N	O
pericarditis	NN	pericarditis	pericarditis	pericard	Y	B-AdverseReaction

Ear	NN	ear	ear	ear	N	O
and	CC	and	and	and	N	O
Labyrinth	JJ	labyrinth	labyrinth	labyrinth	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
tinnitus	NN	tinnitus	tinnitus	tinnitu	Y	B-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
gastritis	NN	gastritis	gastritis	gastriti	Y	B-AdverseReaction
;	:	;	;	;	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
-	:	-	-	-	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
includes	VBZ	includes	includes	includ	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastric	JJ	gastric	gastric	gastric	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administrative	NNP	administrative	administrative	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
includes	VBZ	includes	includes	includ	N	O
chest	NN	chest	chest	chest	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
and	CC	and	and	and	N	O
chest	VB	chest	chest	chest	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
(	(	(	(	(	N	O
includes	VBZ	includes	includes	includ	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
,	,	,	,	,	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cytolytic	JJ	cytolytic	cytolytic	cytolyt	N	B-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
hepatic	JJ	hepatic	hepatic	hepat	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
(	(	(	(	(	N	O
includes	VBZ	includes	includes	includ	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
hepatic	JJ	hepatic	hepatic	hepat	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
,	,	,	,	,	N	O
liver	RB	liver	liver	liver	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
)	)	)	)	)	N	O
;	:	;	;	;	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
-	:	-	-	-	N	O
liver	NN	liver	liver	liver	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
drug	NN	drug	drug	drug	N	B-AdverseReaction
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	I-AdverseReaction
;	:	;	;	;	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
-	:	-	-	-	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
includes	VBZ	includes	includes	includ	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchopneumonia	NN	bronchopneumonia	bronchopneumonia	bronchopneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lobar	NN	lobar	lobar	lobar	N	B-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
,	,	,	,	,	N	O
primary	JJ	primary	primary	primari	N	B-AdverseReaction
atypical	JJ	atypical	atypical	atyp	N	I-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
influenza	JJ	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
electrocardiogram	NN	electrocardiogram	electrocardiogram	electrocardiogram	Y	B-AdverseReaction
QT	NNP	qt	qt	qt	N	I-AdverseReaction
prolonged	VBD	prolonged	prolonged	prolong	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
creatine	NN	creatine	creatine	creatin	Y	I-AdverseReaction
phosphokinase	NN	phosphokinase	phosphokinase	phosphokinas	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NNP	nutrition	nutrition	nutrit	N	O
Disorder	NNP	disorder	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorder	NNP	disorder	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NN	system	system	system	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	JJ	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
pleural	JJ	pleural	pleural	pleural	N	B-AdverseReaction
effusion	NN	effusion	effusion	effus	Y	I-AdverseReaction
;	:	;	;	;	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
-	:	-	-	-	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
hypertension	NN	hypertension	hypertension	hypertens	Y	I-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
-	:	-	-	-	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
acne	NN	acne	acne	acn	Y	B-AdverseReaction
;	:	;	;	;	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
-	:	-	-	-	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
multiforme	NN	multiforme	multiforme	multiform	N	I-AdverseReaction
,	,	,	,	,	N	O
exfoliative	JJ	exfoliative	exfoliative	exfoli	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
drug	NN	drug	drug	drug	N	B-AdverseReaction
eruption	NN	eruption	eruption	erupt	Y	I-AdverseReaction
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
manage	NN	manage	manage	manag	N	O
as	IN	as	a	as	N	O
necessary	JJ	necessary	necessary	necessari	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
and	CC	and	and	and	N	O
manage	NN	manage	manage	manag	N	O
as	IN	as	a	as	N	O
necessary	JJ	necessary	necessary	necessari	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
liver	VBD	liver	liver	liver	N	O
enzymes	NNS	enzymes	enzyme	enzym	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
monthly	JJ	monthly	monthly	monthli	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
three	CD	three	three	three	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Fluid	NNP	fluid	fluid	fluid	N	B-AdverseReaction
Retention	NN	retention	retention	retent	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
manage	NN	manage	manage	manag	N	O
using	VBG	using	using	use	N	O
standard	NN	standard	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
Monitor	NNP	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
May	NNP	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

Toxicity	NN	toxicity	toxicity	toxic	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
occur	IN	occur	occur	occur	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
manage	NN	manage	manage	manag	N	O
patients	NNS	patients	patient	patient	N	O
using	VBG	using	using	use	N	O
standards	NNS	standards	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
antidiarrheals	NNS	antidiarrheals	antidiarrheal	antidiarrh	N	O
,	,	,	,	,	N	O
antiemetics	NNS	antiemetics	antiemetic	antiemet	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fluid	JJ	fluid	fluid	fluid	N	O
replacement	NN	replacement	replacement	replac	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
Phase	NNP	phase	phase	phase	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
for	IN	for	for	for	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
(	(	(	(	(	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
2	CD	2	2	2	N	O
days	NNS	days	day	day	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
per	IN	per	per	per	N	O
event	NN	event	event	event	N	O
was	VBD	was	wa	wa	N	O
1	CD	1	1	1	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
per	IN	per	per	per	N	O
patient	NN	patient	patient	patient	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
was	VBD	was	wa	wa	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
221	CD	221	221	221	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
,	,	,	,	,	N	O
withhold	NN	withhold	withhold	withhold	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
as	IN	as	a	as	N	O
necessary	JJ	necessary	necessary	necessari	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
occur	NN	occur	occur	occur	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Perform	NNP	perform	perform	perform	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
weekly	VBP	weekly	weekly	weekli	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
month	NN	month	month	month	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
monthly	JJ	monthly	monthly	monthli	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	O
,	,	,	,	,	N	O
withhold	NN	withhold	withhold	withhold	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
as	IN	as	a	as	N	O
necessary	JJ	necessary	necessary	necessari	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

One	CD	one	one	one	N	O
case	NN	case	case	case	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
drug	NN	drug	drug	drug	N	B-AdverseReaction
induced	VBN	induced	induced	induc	N	I-AdverseReaction
liver	JJ	liver	liver	liver	N	I-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
(	(	(	(	(	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	B-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
with	IN	with	with	with	N	O
total	JJ	total	total	total	N	B-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
2	CD	2	2	2	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
and	CC	and	and	and	N	O
alkaline	JJ	alkaline	alkaline	alkalin	N	B-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
2	CD	2	2	2	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
letrozole	NN	letrozole	letrozole	letrozol	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
recovered	VBD	recovered	recovered	recov	N	O
fully	RB	fully	fully	fulli	N	O
following	VBG	following	following	follow	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
case	NN	case	case	case	N	O
represented	VBD	represented	represented	repres	N	O
1	CD	1	1	1	N	O
out	IN	out	out	out	N	O
of	IN	of	of	of	N	O
1209	CD	1209	1209	1209	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
546	CD	546	546	546	N	O
patients	NNS	patients	patient	patient	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
population	NN	population	population	popul	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
17%	CD	17%	17%	17%	N	O
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
14%	CD	14%	14%	14%	N	O
.	.	.	.	.	N	O

Twenty	CD	twenty	twenty	twenti	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
either	CC	either	either	either	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
early	JJ	early	early	earli	N	O
in	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
;	:	;	;	;	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
transaminase	JJ	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
,	,	,	,	,	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
80%	CD	80%	80%	80%	N	O
experienced	VBD	experienced	experienced	experienc	N	O
their	PRP$	their	their	their	N	O
first	JJ	first	first	first	N	O
event	NN	event	event	event	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
30	CD	30	30	30	N	O
and	CC	and	and	and	N	O
33	CD	33	33	33	N	O
days	NNS	days	day	day	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
for	IN	for	for	for	N	O
each	DT	each	each	each	N	O
was	VBD	was	wa	wa	N	O
21	CD	21	21	21	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

Perform	NNP	perform	perform	perform	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
enzyme	NN	enzyme	enzyme	enzym	N	O
tests	NNS	tests	test	test	N	O
monthly	RB	monthly	monthly	monthli	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
three	CD	three	three	three	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
transaminase	JJ	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
,	,	,	,	,	N	O
monitor	NN	monitor	monitor	monitor	N	O
liver	NN	liver	liver	liver	N	O
enzymes	VBZ	enzymes	enzyme	enzym	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
as	IN	as	a	as	N	O
necessary	JJ	necessary	necessary	necessari	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Fluid	NNP	fluid	fluid	fluid	N	O
Retention	NN	retention	retention	retent	N	O

Fluid	NNP	fluid	fluid	fluid	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
occurs	VBZ	occurs	occurs	occur	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	B-Factor
manifest	VB	manifest	manifest	manifest	N	O
as	IN	as	a	as	N	O
pericardial	JJ	pericardial	pericardial	pericardi	N	B-AdverseReaction
effusion	NN	effusion	effusion	effus	Y	I-AdverseReaction
,	,	,	,	,	N	O
pleural	JJ	pleural	pleural	pleural	N	B-AdverseReaction
effusion	NN	effusion	effusion	effus	Y	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
Phase	NNP	phase	phase	phase	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
546	CD	546	546	546	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CML	NNP	cml	cml	cml	Y	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
prior	JJ	prior	prior	prior	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
fluid	NN	fluid	fluid	fluid	N	B-AdverseReaction
retention	NN	retention	retention	retent	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
14	CD	14	14	14	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Specifically	RB	specifically	specifically	specif	N	O
,	,	,	,	,	N	O
9	CD	9	9	9	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
pleural	JJ	pleural	pleural	pleural	N	B-AdverseReaction
effusion	NN	effusion	effusion	effus	Y	I-AdverseReaction
,	,	,	,	,	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
both	DT	both	both	both	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
Grade	VB	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
pleural	JJ	pleural	pleural	pleural	N	B-AdverseReaction
and	CC	and	and	and	N	O
pericardial	JJ	pericardial	pericardial	pericardi	N	B-AdverseReaction
effusions	NNS	effusions	effusion	effus	N	I-AdverseReaction
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
peripheral	NN	peripheral	peripheral	peripher	N	B-AdverseReaction
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
edema	NN	edema	edema	edema	Y	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
manage	NN	manage	manage	manag	N	O
patients	NNS	patients	patient	patient	N	O
using	VBG	using	using	use	N	O
standards	NNS	standards	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
,	,	,	,	,	N	O
dose	JJ	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
as	IN	as	a	as	N	O
necessary	JJ	necessary	necessary	necessari	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Renal	JJ	renal	renal	renal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

An	DT	an	an	an	N	O
on	IN	on	on	on	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
decline	NN	decline	decline	declin	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
estimated	VBN	estimated	estimated	estim	N	I-AdverseReaction
glomerular	JJ	glomerular	glomerular	glomerular	N	I-AdverseReaction
filtration	NN	filtration	filtration	filtrat	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
(	(	(	(	(	N	O
eGFR	NN	egfr	egfr	egfr	N	O
)	)	)	)	)	N	O
has	VBZ	has	ha	ha	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
identifies	NNS	identifies	identifies	identifi	N	O
the	DT	the	the	the	N	O
shift	NN	shift	shift	shift	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
lowest	VB	lowest	lowest	lowest	N	O
observed	VBN	observed	observed	observ	N	O
estimated	JJ	estimated	estimated	estim	N	O
glomerular	JJ	glomerular	glomerular	glomerular	N	O
filtration	NN	filtration	filtration	filtrat	N	O
rate	NN	rate	rate	rate	N	O
(	(	(	(	(	N	O
eGFR	NN	egfr	egfr	egfr	N	O
)	)	)	)	)	N	O
during	IN	during	during	dure	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
therapy	NN	therapy	therapy	therapi	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
global	JJ	global	global	global	N	O
Ph	NNP	ph	ph	ph	Y	O
Leukemia	NNP	leukemia	leukemia	leukemia	Y	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
17	CD	17	17	17	N	O
months	NNS	months	month	month	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
0.03	CD	0.03	0.03	0.03	N	O
to	TO	to	to	to	N	O
95	CD	95	95	95	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Shift	NN	shift	shift	shift	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
Lowest	NNP	lowest	lowest	lowest	N	O
Observed	NNP	observed	observed	observ	N	O
eGFR	NN	egfr	egfr	egfr	N	O
Group	NNP	group	group	group	N	O
During	IN	during	during	dure	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Safety	NNP	safety	safety	safeti	N	O
Population	NNP	population	population	popul	N	O
in	IN	in	in	in	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
818	CD	818	818	818	N	O
)	)	)	)	)	N	O
Among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
818	CD	818	818	818	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
eGFR	NN	egfr	egfr	egfr	N	O
was	VBD	was	wa	wa	N	O
missing	VBG	missing	missing	miss	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
or	CC	or	or	or	N	O
on	IN	on	on	on	N	O
-	:	-	-	-	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
kidney	JJ	kidney	kidney	kidney	N	O
failure	NN	failure	failure	failur	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
Follow	NNP	follow	follow	follow	N	O
Up	NNP	up	up	up	N	O

Renal	JJ	renal	renal	renal	N	O
Function	NNP	function	function	function	N	O
Status	NNP	status	status	statu	N	O
n	FW	n	n	n	N	O
Normaln	NNP	normaln	normaln	normaln	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Mildn	NNP	mildn	mildn	mildn	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Mild	NNP	mild	mild	mild	N	O
to	TO	to	to	to	N	O
Moderaten	NNP	moderaten	moderaten	moderaten	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Moderate	NNP	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
Severen	NNP	severen	severen	severen	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Severen	NNP	severen	severen	severen	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Kidney	NNP	kidney	kidney	kidney	N	B-AdverseReaction
Failuren	NNP	failuren	failuren	failuren	N	I-AdverseReaction
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Notes	NNS	notes	note	note	N	O

:	:	:	:	:	N	O
Grading	NN	grading	grading	grade	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
Modification	NNP	modification	modification	modif	N	O
in	IN	in	in	in	N	O
Diet	NNP	diet	diet	diet	N	O
in	IN	in	in	in	N	O
Renal	NNP	renal	renal	renal	N	O
Disease	NNP	disease	disease	diseas	N	O
method	NN	method	method	method	N	O
(	(	(	(	(	N	O
MDRD	NNP	mdrd	mdrd	mdrd	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
KDIGO	NNP	kdigo	kdigo	kdigo	N	O
Classification	NNP	classification	classification	classif	N	O
by	IN	by	by	by	N	O
eGFR	NN	egfr	egfr	egfr	N	O
:	:	:	:	:	N	O
Normal	NN	normal	normal	normal	N	O
:	:	:	:	:	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
90	CD	90	90	90	N	O
,	,	,	,	,	N	O
Mild	NNP	mild	mild	mild	N	O
:	:	:	:	:	N	O
60	CD	60	60	60	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
90	CD	90	90	90	N	O
,	,	,	,	,	N	O
Mild	NNP	mild	mild	mild	N	O
to	TO	to	to	to	N	O
Moderate	NNP	moderate	moderate	moder	N	O
:	:	:	:	:	N	O
45	CD	45	45	45	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
,	,	,	,	,	N	O
Moderate	NNP	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
Severe	NNP	severe	severe	sever	N	O
:	:	:	:	:	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
45	CD	45	45	45	N	O
,	,	,	,	,	N	O
Severe	NNP	severe	severe	sever	N	O
:	:	:	:	:	N	O
15	CD	15	15	15	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
30	CD	30	30	30	N	O
,	,	,	,	,	N	O
Kidney	NNP	kidney	kidney	kidney	N	O
Failure	NN	failure	failure	failur	N	O
:	:	:	:	:	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
15	CD	15	15	15	N	O
ml	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Normal	JJ	normal	normal	normal	N	O

274	CD	274	274	274	N	O
53	CD	53	53	53	N	O
(	(	(	(	(	N	O
19	CD	19	19	19	N	O
)	)	)	)	)	N	O
174	CD	174	174	174	N	O
(	(	(	(	(	N	O
64	CD	64	64	64	N	O
)	)	)	)	)	N	O
30	CD	30	30	30	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Mild	NNP	mild	mild	mild	N	O
438	CD	438	438	438	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
170	CD	170	170	170	N	O
(	(	(	(	(	N	O
39	CD	39	39	39	N	O
)	)	)	)	)	N	O
177	CD	177	177	177	N	O
(	(	(	(	(	N	O
40	CD	40	40	40	N	O
)	)	)	)	)	N	O
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Mild	NNP	mild	mild	mild	N	O
to	TO	to	to	to	N	O
Moderate	NNP	moderate	moderate	moder	N	O
79	CD	79	79	79	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
28	CD	28	28	28	N	O
(	(	(	(	(	N	O
35	CD	35	35	35	N	O
)	)	)	)	)	N	O
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
47	CD	47	47	47	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Moderate	NNP	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
Severe	NNP	severe	severe	sever	N	O
24	CD	24	24	24	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
63	CD	63	63	63	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Severe	RB	severe	severe	sever	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
100	CD	100	100	100	N	O
)	)	)	)	)	N	O

Total	JJ	total	total	total	N	O
816	CD	816	816	816	N	O
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
349	CD	349	349	349	N	O
(	(	(	(	(	N	O
43	CD	43	43	43	N	O
)	)	)	)	)	N	O
236	CD	236	236	236	N	O
(	(	(	(	(	N	O
29	CD	29	29	29	N	O
)	)	)	)	)	N	O
120	CD	120	120	120	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
)	)	)	)	)	N	O
40	CD	40	40	40	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
particular	JJ	particular	particular	particular	N	O
attention	NN	attention	attention	attent	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
preexisting	VBG	preexisting	preexisting	preexist	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
or	CC	or	or	or	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
renal	JJ	renal	renal	renal	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
dose	JJ	dose	dose	dose	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
emergent	JJ	emergent	emergent	emerg	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.7	CD	2.7	2.7	2.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O

Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
no	DT	no	no	no	N	O
adequate	JJ	adequate	adequate	adequ	N	O
and	CC	and	and	and	N	O
well	RB	well	well	well	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
in	IN	in	in	in	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
.	.	.	.	.	N	O

BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Bosutinib	NNP	bosutinib	bosutinib	bosutinib	N	O
caused	VBD	caused	caused	caus	N	O
embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
in	IN	in	in	in	N	O
rabbits	NNS	rabbits	rabbit	rabbit	N	B-Animal
at	IN	at	at	at	N	O
maternal	JJ	maternal	maternal	matern	N	O
exposures	NNS	exposures	exposure	exposur	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
exposure	NN	exposure	exposure	exposur	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
bosutinib	NN	bosutinib	bosutinib	bosutinib	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
500	CD	500	500	500	N	O
mg	JJ	mg	mg	mg	N	O
day	NN	day	day	day	N	O
.	.	.	.	.	N	O

Females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
while	IN	while	while	while	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
BOSULIF	NNP	bosulif	bosulif	bosulif	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

